Controlled transdermal delivery of propranolol using HPMC matrices: Design and in-vitro and in-vivo evaluation

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 2, 2000, Pages 151-156

  Verma, P R P ^a   Iyer, Sunil S ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; PROPRANOLOL;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PLASMA; TRANSDERMAL PATCH; URINARY EXCRETION;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HALF-LIFE; HUMANS; KINETICS; MALE; METHYLCELLULOSE; PROPRANOLOL;

EID: 0034047079     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001773797     Document Type: Article

References (16)

1. Ademola, J. I., Chow, C. A., Wester, R. C., Maiback, H. I. (1993) Metabolism of propranolol during percutaneous absorption in human skin. J. Pharm. Sci. 82: 767-770
2. Barnwell, S. G., Laudanski, T., Story, M. L., Mallinson, C. B., Harries, R. J., Cole, S. K., Keating, M., Attwood, D. (1992) Improved oral bioavailability of propranolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid. Int. J. Pharm. 88: 423-432
3. Chien, Y. W. (1983) Logics of transdermal controlled drug administration. Drug Dev. Ind. Pharm. 9: 497-520
4. Connie Chang, M. M., Lee, P. H., Broman, C. T., Cleary, G. W. (1993) New improved paddle method for determining the in-vitro drug release profile of transdermal delivery systems. J. Contr. Rel. 27: 59-68
5. Corbo, M., Liu, J. C., Chien, Y. W. (1990) Bioavailability of propranolol following oral and transdermal administration in rabbits. J. Pharm. Sci. 79: 584-587
6. Gomeni, R., Bianchetti, G., Sega, R., Morselli, P. L. (1977) Pharmacokinetics of propranolol in normal healthy volunteers. J. Pharmacokin. Biopharm. 5: 183-191
7. Guy, R. H. (1996) Current status and future prospects of transdermal drug delivery. Pharm. Res. 13: 1765
8. Loftsson, T., Gildersleeva, N., Boder, N. (1987) The effect of vehicle additives on the transdermal delivery of nitroglycerin. Pharm. Res. 4: 436
9. McClave J. T., Benson, P. G. (1990) Statistics for Business and Economics. 4th edn, Collier MacMillan, London, pp 1198-1212
10. Monkhouse, D. C., Haq, A. S. (1988) Transdermal drug delivery - problems and promises. Drug Dev. Ind. Pharm. 14: 183-209
11. Reynolds, J. E. F. (1989) Martindale, The Extra Pharmacopoeia. 29th edn, The Pharmaceutical Press, London, p. 803
12. Riddell, J. G., Haron, D. W. G., Shanks, R. G. (1987) Clinical pharmacokinetics of β-adrenoceptor antogonist. An update. Clin. Pharmacokin. 12: 305-320
13. Ritschel, W. A. (1984) Graphical Approach to Clinical Pharmacokinetics. 2nd edn, J. R. Prous, Barcelona, pp 19-25
14. Shah, V. P., Tymes, N. W., Yamamoto, L. A., Skell, J. P. (1986) In-vitro dissolution profiles of transdermal nitro-glycerine patches using paddle method. Int. J. Pharm. 32: 243-250
15. Trivedi, B. M., Gohel, M., Chawda, H. (1986) Fluorometric determination of propranolol. Ind. J. Pharm. Sci. 48: 142-143
16. Wiechers, J. W. (1989) The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm. Weekbl. 11: 185-198